CHROMATIN STRUCTURE AND FUNCTION ARE DYNAMICALLY regulated in stem cells of the brain, which serve as an important paradigm for understanding the regulatory mechanisms that transduce physiological and pathophysiological signals to the stem cell genome. In the adult vertebrate brain, the production of newborn neurons from stem cells (neurogenesis) takes place in discrete proliferation zones (niches), such as the subventricular zone (SVZ) of the lateral ventricle and the subgranular zone (SGZ) of the dentate gyrus of the hippocampus (Gage 2000) . A variety of signals, ranging from excitation due to locally released neurotransmitters to systemic factors or drugs that cross the blood-brain barrier, converge upon clusters of neuronal stem/progenitor cells (NSCs) residing in these niches, which are intimately associated with the cerebral microvasculature. Balanced control of self-renewal, differentiation, and survival of NSCs produces new neurons and glial cells necessary for functional homeostasis of the brain and also has an important role in brain function such as memory and learning. Moreover, as potential cancer stem cells, NSCs are suspected to be the root of brain malignancies such as glioblastoma multiforme. To become neurons, NSCs require coordinated changes in the pattern of gene expression, primarily regulated at the level of gene transcription. Epigenetic chromatin remodeling has emerged as a fundamental higher-order mechanism for fine-tuning and coordinating gene expression during neurogenesis. Important aspects of brain function such as synaptic plasticity are also governed by chromatin-remodeling enzymes, cell-type-specific transcriptional regulators, and small regulatory noncoding RNAs. Thus, signaling to the genome through diverse epigenetic regulatory mechanisms is critical to neurogenesis and brain function during development and throughout life.
Although it is a relatively new concept in neuroscience, the importance of epigenetic mechanisms has been appreciated for many years in the developmental and cancer biology fields. Indeed, drugs that act on epigenetic mechanisms are already in cancer clinical trials. Classical epigenetic processes, such as X-chromosome inactivation, imprinting, and gene silencing, have been studied in traditional model systems such as plants, invertebrates, and mice. At this time, epigenetic mechanisms are considered equally important to sequence-specific DNA-binding transcription factors as regulators of gene expression. Among the most commonly employed definitions of epigenetics are meiotically and mitotically heritable changes in patterns of gene expression that are not encoded in the primary DNA sequence itself, essentially a term to describe alterations that lead to new cellular phenotypes without a change in genotype. In this sense, epigenetic changes in chromatin organization and biochemical modifications allow genotypically identical cells to behave phenotypically different. Much of the basic cellular chromatin and transcriptional machinery has been elucidated from biochemical approaches and the use of simple genetic model organisms. However, a full understanding of the signaling circuitry and transcriptional regulatory mechanisms in complex organs such as the mammalian brain remains sketchy. This chapter presents key aspects of the epigenetic regulation of adult neurogenesis and the convergence of epigenetic mechanisms that govern the neuronal genome in both normal and disease states.
CHROMATIN STRUCTURE AND HISTONE MODIFICATIONS
Chromatin is a nucleoprotein complex composed of nucleosome repeats of 147 bp of DNA sequence physically wrapped around two copies each of the histonal proteins, H2A, H2B, H3, and H4 (Luger and Richmond 1998) . One of the most exciting breakthroughs in chromatin biology in this last decade is the discovery that the amino-terminal tails of core histones are subject to a variety of covalent modifications such as acetylation and methylation and that DNA site-or domain-specific histone modifications ("the histone code") control the activation or repression of the associated genes (Jenuwein and Allis 2001) . Some histone marks such as acetylation of Lys-9 and Lys-14, di-or trimethylation of Lys-4, and phosphorylation of Ser-10 on histone H3 are signatures of actively expressed chromatin. Other marks, such as di-or trimethylation of Lys-9 on histone H3 are associated with silent chromatin domains. The histone code is specified by chromatin-modifying enzymes such as histone acetyltransferases (HATs), histone deacetylases (HDACs), and histone methyltransferases (HMTs), which are targeted to specific chromatin loci through direct association with sequence-specific DNA-binding proteins in large, multicomponent complexes. Many of the components of these complexes, even the chromatin-modifying enzymes themselves, are signal-responsive, resulting in a complex regulatory hierarchy for control of the genome.
The HATs and HDACs are the most extensively studied chromatinmodifying enzymes. HATs induce histone acetylation that usually results in relaxation of the nucleosomes and increased transcription, whereas HDACs catalyze the reverse reaction; in the deacetylated state, nucleosomes are more condensed, preventing access of transcriptional activators to their target sites which results in transcriptional repression. In terms of the brain, global changes in histone modifications have been observed in different regions, particularly after traumatic brain injury, electroconvulsive seizures, or drugs of abuse such as cocaine (Crosio et al. 2003; Tsankova et al. 2004; Gao et al. 2006; Sng et al. 2006) . Although these findings are intriguing, the role of cell-type-specific histone-modifying enzymes in neural development and function remains to be determined. One class of tissue-specific HDACs (class II) has a well-documented signal-responsive role in controlling cardiac muscle cell hypertrophy (Nakagawa et al. 2006) ; this class of enzyme is also highly enriched in the developing and adult brain (Thiagalingam et al. 2003 ), yet little is known regarding the specific function of class II HDACs in neurobiology. One important clue regarding the role of class I and class II HDACs comes from small-molecule HDAC inhibitors (HDACi) such as trichostatin A or valproic acid (VPA) (Grozinger and Schreiber 2002) . HDACi can induce neuronal differentiation in embryonic (Hao et al. 2004 ) and adult neuronal progenitor cells ). In our own work, we found that VPA treatment in rats decreased NSC proliferation in the SGZ ) and, in seizure animals, attenuated the aberrant neurogenesis associated with seizures and, most importantly, improved cognitive function (Jessberger et al. 2007 ). These results suggest that pharmacological inhibition of HDAC activity might become an effective clinical strategy for treating seizure disorders and epilepsy. Moreover, due to their neuroprotective effects, HDACi epigenetic drugs have shown therapeutic promise in humans or animal models of Huntington's disease (Butler and Bates 2006) , amyotrophic lateral sclerosis (Petri et al. 2006 ), Friedreich's ataxia (Herman et al. 2006) , spinal muscular atrophy (Hahnen et al. 2006) , ischemic brain injury (Faraco et al. 2006) , seizure disorders (Eyal et al. 2004) , and even brain cancer cells (Komata et al. 2005; van den Boom et al. 2006) . The future application of HDACi for treating CNS disorders remains an exciting possibility and, combined with our increasing understanding of NSCs in the adult brain, can be a powerful approach to combating neurological disease. These global studies of histone modifications and HDACi in neurological disorders and brain function are intriguing; however, detailed studies are needed to understand how specific genes are regulated to control neuronal stem-cell-fate decisions.
CHROMATIN COMPLEXES CONTROLLING NEURONAL CELL FATE
One of the best-characterized mechanisms for regulating HDAC activity in the cell involves signal-responsive export of the active class II enzyme from the nucleus and derepression of gene expression (Grozinger and Schreiber 2000; McKinsey et al. 2000) . A second, perhaps even more common, mechanism involves the recruitment of HDACs and multiprotein chromatin-remodeling complexes to gene-specific promoters by association with DNA-binding proteins (Grozinger and Schreiber 2002) . During cortical development, NSCs first undergo limited expansion through rounds of symmetric divisions and then undergo neurogenesis, mainly through asymmetric divisions (Temple 2001) . Toward the end of neurogenesis, cortical progenitors switch back to symmetric divisions and give rise to astrocytes and oligodendrocytes. Cell-fate specification toward neuronal or glial lineages involves the reciprocal regulation of several gene batteries. For example, the genes responsible for the specification of neuronal cells must be repressed or silenced when the developing NSC diverges toward astrocytic or oligodendrocytic cell fate, and, vice versa, gliogenic genes must be inhibited during neurogenesis. This is coordinated through both transcriptional and epigenetic regulatory mechanisms that determine the potential of the cell to respond to extrinsic signals ( Fig. 1) . Many elegant studies collectively describe the existence of transcriptional codes involving the spatial and temporal expression of cell-type-specific transcriptional activators and repressors that control neuronal subtype specification and patterning in the developing CNS (Bertrand et al. 2002; Ross et al. 2003) . Many of these factors have been studied in terms of their regulation of individual target genes during neural specification; however, a unifying mechanism that controls the process of neuronal cell fate specification through maturation has not been found.
A candidate master regulator for neurogenesis and gliogenesis is the transcriptional regulator NRSF (neuron-restrictive silencing factor, also called REST) (Chong et al. 1995; Schoenherr and Anderson 1995) . Initially described as a repressor of neuronal genes in nonneuronal cells, NRSF is a zinc finger protein that binds to a conserved 21-23-bp motif known as NRSE (neuron-restrictive silencing element, also called RE1). The NRSE sequence is found scattered throughout the genome, many in the regulatory regions of neuron-specific genes, including neuronal growth factors, ion channels, neurotransmitter receptors, and guidance/migration molecules, among other important neurogenic genes. The precise mechanism by which NRSF mediates transcriptional regulation of its target genes remains a mystery; in certain gene contexts, NRSF acts as a repressor, whereas in other contexts, it acts as an activator of gene transcription. Emerging evidence suggests that NRSF functions by recruiting other corepressor complexes, such as mSin3A/B (Naruse et al. 1999) , N-CoR (Jepsen et al. 2000) , CtBP (Garriga-Canut et al. 2006) , or CoREST (Ballas et al. 2001) , to specific RE1 sites in the genome. Importantly, these regulatory complexes also recruit chromatin-modifying class I HDAC enzymes to the genome. Recently, Nakagawa et al. (2006) demonstrated direct interaction between NRSF and class II HDACs in ventricular cardiac muscle cells in vivo and in vitro (Nakagawa et al. 2006) . Bioinformatics analyses have identified hundreds to thousands of NRSE sites throughout the mammalian genome (Bruce et al. 2004) , supporting the idea that NRSF functions as a master regulator of neuronal gene expression in NSCs as well as in mature neurons (Sun et al. 2005; Greenway et al. 2006) . Recently, NRSF was found to be important for triggering adult hippocampal neurogenesis from NSCs by acting as an activator of neuronal gene expression ). The mechanism of NRSF action in adult NSCs appeared to involve a novel noncoding double-stranded RNA (discussed in another section). To add to the intrigue, NRSF function has also been implicated in various pathological states in the brain as well as outside the brain, such as in different kinds of neuronal and neuroendocrine cancer cells (Coulson 2005 ), Huntington's disease (Zuccato et al. 2003) , ischemic insults (Calderone et al. 2003) , epilepsy (Garriga-Canut et al. 2006) , and cardiovascular disease (Cheong et al. 2005) .
In addition to neuronal gene regulation by NRSF and recruitment of histone-modifying enzymes, recent evidence suggests that members of the SWI/SNF and Polycomb family of chromatin-remodeling complexes have important roles in neural development and cancer and stem cell biology (Cui et al. 2006; Lee et al. 2006) . Chromatin-remodeling complexes such as SWI/SNF use ATP hydrolysis to disrupt histone-DNA associations and contain different combinations of proteins that include both conserved and nonconserved components (Becker and Horz 2002) . They also interact with HATs or HDACs and/or sequence-specific transcription factors to activate or repress target genes. Typically, SWI/SNF complexes contain either the ATPase Brahma (Brm) or Brahma-related protein 1 (Brg-1). Chromodomain proteins, which possess the ATPase domain found in SWI/SNF proteins, are also recruited by Polycomb repressors and are involved in homeotic gene silencing to control tissue patterning. Recently, Brm, Brg-1, and the Polycomb repressor protein Bmi-1 have all been implicated in some aspect of neural development and function. The SRY-related HMG-box-containing protein (Sox-2) is a key transcription factor in NSCs, and the recruitment of Brm for its own transcriptional regulation appears to be linked to its role in stem cell maintenance (Kondo and Raff 2004) . Brg-1 is also required for Xenopus neurogenesis; loss of Brg-1 correlated with increased neuronal progenitor proliferation and an expansion of Sox2-positive cells in embryos at later stages of neurogenesis. Brg-1 function appears to be linked to the regulation of two proneural basic helix-loop-helix (bHLH) proteins: Neurogenin (Ngn)-related 1 and NeuroD (Seo et al. 2005) . Moreover, the Polycomb group proteins are emerging to have fundamental roles in stem cell maintenance and cancer. Bmi-1 is required for the self-renewal of stem cells in the CNS and PNS; mice lacking Bmi-1 experience neurological defects, presumably due to a postnatal depletion of their NSCs (van der Lugt et al. 1994; Molofsky et al. 2003 Molofsky et al. , 2005 . Together, these data indicate the important role of chromatin-remodeling factors in brain development and function; the exact role of ATP-dependent chromatin-remodeling complexes remains to be determined.
CHROMATIN REMODELING AND ADULT NEUROGENESIS
In addition to development, transcriptional coactivators and chromatinremodeling factors are also emerging to be important for adult neurogenesis. Querkopf (Qkf)-deficient mice, a MYST family histone acetyltransferase, have fewer NSCs and fewer migrating neuroblasts in the rostral migratory stream of the adult SVZ (Merson et al. 2006) . Furthermore, neurospheres derived from Qkf mutant mice contain fewer cells with the potential to generate secondary neurospheres and form fewer neurons, suggesting that Qkf mutant stem cells have a defect in selfrenewal and lineage specification in vitro. Under similar conditions, the nuclear corepressor (N-CoR) is also required to suppress astrocyte differentiation and promote neuronal differentiation (Hermanson et al. 2002) , suggesting commonalities in the transcriptional machinery regulating neuronal lineage differentiation. Many of the HDAC proteins themselves have been characterized exclusively with respect to heart function; virtually nothing is known regarding their roles in the brain, particularly during adult neurogenesis. Interestingly, a study profiling the gene expression patterns associated with SVZ neurogenesis revealed an up-regulation of chromatin modifiers belonging to the SWI/SNF and Polycomb/Trithorax family of proteins (Lim et al. 2006) , raising the possibility that chromatin remodeling may be important for the maintenance of the stem cell state by keeping lineage specification genes repressed, but primed to receive a specific extrinsic signal. Another important epigenetic modification implicated in adult neurogenesis is methylation of CpG dinucleotides (discussed in the next section).
THE ROLE OF DNA METHYLATION IN THE BRAIN
A classically studied epigenetic modification is DNA methylation where mammalian DNA can be covalently modified through methylation of the carbon at the fifth position on the pyrimidine ring of the cytosine residue, which is usually found at symmetrical CpG dinucleotides. DNA methylation is a major epigenetic mechanism for the establishment of parental-specific imprints during gametogenesis and gene silencing of the inactivated X chromosome and retrotransposons (Jaenisch and Bird 2003) . DNA methylation is mediated by cellular methyltransferases, Dnmt3a and Dnmt3b, which add methyl groups de novo onto unmethylated DNA. When cells divide, the methyltransferase Dnmt1 preferentially recognizes hemimethylated DNA and maintains DNA methylation. Interestingly, both classes of methyltransferases have been shown to participate in various stages of neural fate and neurogenesis. During the initial specification of neurons and glia (Feng et al. 2005) , as well as during later stages of neuronal maturation and function (Levenson et al. 2006 ), Dnmt3a and Dnmt3b are important. Dnmt1 is also very important in the brain and involved in JAK-STAT signaling to control the timing of when precursor cells switch from neurogenesis to gliogenesis during development (Fan et al. 2001 . Site-specific methylation of DNA has been shown to be important for astrocyte differentiation and activation of the glial fibrillary acidic protein (GFAP) promoter. Activation of the GFAP promoter requires binding of the signal transducer and activator of transcription 3 (STAT3) in response to leukemia inhibitory factor (LIF) signaling (Ross et al. 2003) . Early cortical progenitors are refractory to astrocyte fates, even in the presence of LIF and STAT3 activation, likely due to methylation of the STAT3-binding site, which prevents STAT3 binding to the GFAP promoter (Takizawa et al. 2001) . At later stages, this site becomes demethylated, and gliogenesis can proceed. A similar case was observed in the STAT3-binding site of the S100β promoter, a calciumbinding protein expressed in astrocytes (Namihira et al. 2004 ). This directly demonstrates the role of a specific epigenetic mark on neuronal cell-fate specification.
In addition to DNA methylation, histone methylation has also been found to be important for the regulation of the GFAP gene in cortical progenitors. Using chromatin immunoprecipitation (ChIP) assays, Song and Ghosh (2004) showed that there was increased histone H3 Lys-9 methylation, a mark associated with gene silencing, at the STAT3-binding site within GFAP at progenitor stages, when GFAP was repressed. Stimulation with basic fibroblast growth factor-2 (FGF-2) potentiated the ability of CNTF (ciliary neurotrophic factor) to induce astrocyte differentiation. Strikingly, FGF-2 induction caused Lys-9 to become demethylated, but Lys-4, the active mark, to become hypermethylated, resulting in STAT3 binding and activation of GFAP. In contrast, mature neurons had low levels of both Lys-9 and Lys-4 methylation. Still remaining is the question of how GFAP or astrocytic genes are repressed in neurons and whether there are factors that actively promote gliogenesis, without necessarily blocking neurogenesis. In fact, a recent study identified two nuclear factor proteins (NF1A and NF1B) for the initial specification of gliogenesis (Deneen et al. 2006) . These studies highlight the diverse transcriptional and epigenetic mechanisms that control lineage-specific gene expression for the generation of different neuronal cell types during development and throughout adulthood.
The world of epigenetic and histone modifications is becoming increasingly complex and fascinating. Recently, histone arginine methylation has been shown to regulate the pluripotent state of cells in the inner cell mass and, intriguingly, may be among the first set of "marks" that contribute to the pluripotent state (Torres-Padilla et al. 2007) . These types of studies will likely extend to adult neurogenesis, where stem cells still retain multipotency but are no longer pluripotent. Understanding both the epigenetic and genetic determinants of plasticity is important for determining how to utilize and manipulate stem cells for regenerative medicine.
EPIGENETICS AND NEURODEVELOPMENTAL DISORDERS
There are many examples of how epigenetic regulation controls lineagespecific gene expression during development and in adult neurogenesis; however, epigenetic control mechanisms also have an important functional role in mature postmitotic neurons in the brain. As described in the previous section, DNA methylation can mediate silencing by interfering with transcription factor binding to target genes by methylation at CpG sites. Another mechanism by which DNA methylation leads to transcriptional gene silencing is the binding of methyl-CpGs by methylCpG-binding proteins (MBDs), which further recruit HDAC repressor complexes, leading to the formation of repressive chromatin. MBDs comprise a family of proteins, two of which (MeCP2 and MBD1), and possibly more, are turning out to have important roles in the nervous system. MeCP2 is found highly enriched in postmitotic neurons (Zoghbi 2003) , and mutations in MeCP2 have been linked to the neurological disorder Rett syndrome (Guy et al. 2001; Jung et al. 2003) . Rett syndrome is characterized by normal development until 1 year of age, is most commonly seen in females, and is followed by a rapid deterioration, involving loss of speech and motor skills, microcephaly, seizures, autism, ataxia, and stereotypical hand wringing (Rett 1966) . Although the exact role of MeCp2 in neurons is unclear, mounting evidence sug-gests that MeCP2 is a key regulator of the essential brain protein, brainderived neurotrophic factor (BDNF) (West et al. 2002) , but may regulate many more target genes yet to be uncovered. Interestingly, exposure of neurons to elevated levels of extracellular potassium resulted in the phosphorylation of MeCP2 and transcriptional derepression of the BDNF promoter (Chen et al. 2003; Martinowich et al. 2003) . Phosphorylation of MeCP2 at a specific amino acid residue, S421, has recently been shown to occur selectively in the nervous system and is important for regulating dendritic growth and spine maturation and to explain, at least in part, the neuron-specific pathology of Rett syndrome (Zhou et al. 2006 ). Other MBD proteins may also have roles in the brain, particularly during adult neurogenesis. MBD1 knockout mice have diminished hippocampal neurogenesis, defects in spatial learning, and a reduction in long-term potentiation in the dentate gyrus of the hippocampus (Zhao et al. 2003) .
Another commonly inherited mental retardation syndrome is Fragile X. Patients have excessive expansion of the CGG sequence from the 5′UTR (untranslated region) of the Fmr1 gene, resulting in transcriptional silencing of the gene. When the CGG repeats exceed 200, the region is hypermethylated, preventing the binding of transcriptional machinery. Treatments with DNA demethylating drugs result in decreased histone H3 methylation at the Lys-9 residue, increased H3 and H4 acetylation, and decreased methylation at histone H3 Lys-4, resulting in the activation of Fmr1 (Tabolacci et al. 2005 ). This finding strongly suggests a role for chromatin remodeling in the silencing of Fmr1. It appears that MeCP2 and Brm can associate and jointly silence the Fmr1 gene. RNA interference (RNAi) knockdown of MeCP2 and Brm resulted in increased mRNA transcription of Fmr1. These emerging studies suggest that epigenetic factors contribute to neurological disorders such as Rett syndrome and Fragile X mental retardation and represent a new avenue of therapeutic targets.
EPIGENETIC CONTROL OF NEURAL PLASTICITY, LEARNING, AND MEMORY
Epigenetic mechanisms have also been suggested to underlie certain forms of memory and neural plasticity, especially after stress signals, some of which are physiological and others of which are pathological (Fig. 2) . Experimental evidence has implicated histone modifications and chromatin-remodeling factors in animal models of drug addiction, as well as certain types of learning (Colvis et al. 2005) . Since drug addiction has a long-term sustained effect, evidence is leading to alterations in brain cell chromatin structure as the possible underlying mechanism to mediate long-lasting changes in gene expression associated with the drug-addicted state. c-fos and ΔFosB, members of the Fos family of transcription factors, are implicated in behavioral responses and synaptic plasticity induced by abused drugs. Interestingly, cocaine can induce H4 acetylation and H3 phosphoacetylation at the c-fos gene promoter in the striatum after acute administration but is desensitized after repeated exposure to cocaine . As for the FosB promoter, H3 acetylation is still observed under chronic cocaine treatment. ΔFosB, a product of the fosB gene, also known to accumulate under chronic cocaine exposure, increases Figure 2 . Signaling to the genome through diverse epigenetic regulatory mechanisms is critical to neurogenesis and brain function. Environmental or behavioral stimulation, both physiological (such as voluntary exercise) and pathological (such as seizure induction or drugs of addiction), can lead to global changes in histone modifications and chromatin remodeling of target genes controlling the neuronal genome. These context-dependent alterations in chromatin structure and transcriptional activity could produce acute changes in neuronal stem cell proliferation, differentiation, and survival of cells (neurogenesis), as well as cause a long-term sustained effect. The epigenetic machinery could then serve as a key mediator acting at the cellular and molecular levels, sensing perturbations in the environment and triggering long-lasting changes in gene expression associated with various disease or pathological states.
the binding of Brg-1 (a component of the SWI-SNF complex mentioned earlier) with cyclin-dependent kinase 5, a gene implicated in neurogenesis, synaptic plasticity, learning, and memory (Nikolic et al. 1996; Angelo et al. 2006) . This evidence suggests that ΔFosB can recruit chromatinremodeling factors such as HATs and Brg-1-containing complexes to its downstream targets, therefore regulating the expression of key genes involved in sustaining the long-term effects of drugs of abuse.
Epigenetic modifications have also been linked to changes in neural plasticity and long-term memory (Kandel 2001) . Recently, two different mouse models for Rubinstein-Taybi syndrome (RTS), a well-defined congenital syndrome composed of mental retardation, postnatal growth deficiency, microcephaly, specific facial characteristics, broad thumbs, and big toes (Rubinstein and Taybi 1963) , which is genetically linked to the CREBbinding protein (CBP) HAT (Petrij et al. 1995) , have been used to demonstrate that histone acetylation is required for long-term potentiation, learning, and memory (Alarcon et al. 2004; Korzus et al. 2004) . CBP heterozygotes exhibited normal levels of short-term memory; however, their longterm memory, determined as contextual and cued fear conditioning and novel object recognition tasks, was significantly abnormal. Interestingly, when the HDAC inhibitor suberoylanilide hydroxamic acid was delivered intraventricularly into CBP heterozygotes, the mice showed improvement in contextual fear conditioning. In a second mouse model bearing a hippocampal CA1-and dentate-gyrus-specific inducible form of mutant CBP lacking HAT activity, there were long-term memory deficits, although shortterm memory appeared to be intact. Similarly, when an HDAC inhibitor trichostatin A was used, or when the transgene was shut off, the memory deficits could be rescued, suggesting that pharmacological manipulation of HAT activity might be a potential therapeutic approach to treat RTS. Perhaps more importantly, the findings that genes such as CBP and MeCP2, which have such global effects on gene expression, have such specific phenotypic consequences in the brain, suggest that epigenetic mechanisms may represent an untapped area for understanding and treating cognitive disorders. A more comprehensive discussion and review of neurodevelopmental and cognitive disorders linked to transcriptional regulators have been described and discussed elsewhere (Hong et al. 2005) .
REGULATORY SMALL RNAS IN THE BRAIN
The discovery of small noncoding RNAs has revolutionized our understanding of the mechanisms that regulate gene expression in all cells (Novina and Sharp 2004) , including those of the mammalian brain (Cao et al. 2006) . Their small size and sequence complementarity allow extreme versatility to target mRNAs for repression or activation of gene expression or modify chromatin structures of targeted genes. Doublestranded RNA was originally found to silence genes by targeting their mRNA intermediates for degradation, but during the past several years, further mechanisms of action of small RNAs have been discovered and potential new classes of such RNAs have been revealed. Small RNAs fall into at least four major classes. Small interfering RNAs (siRNAs) and microRNAs (miRNAs) both silence gene expression; siRNAs usually target mRNAs for degradation by sequence complementarity to a single site, whereas miRNAs recognize numerous partially complementary binding sites that act synergistically within target mRNAs found to be abundantly distributed in the postnatal brain, suggesting that they have important roles in neuronal function. Of the approximately 250 miRNAs in mammals, it would appear that at least 125 miRNAs are expressed in the brain at various levels (Krichevsky et al. 2003; Sempere et al. 2004 ). Some of these miRNAs found in brain are miR9, miR29, miR124, miR125a, miR125b, miR127, miR128, miR132, miR137, miR138, and miR139, among the ever-growing list. Recently, a CREB-induced miRNA (miR132) was found to regulate neuronal morphogenesis in cultured cortical neurons (Vo et al. 2005) . Another miRNA implicated in neuronal function is miR134, which is dendritically localized and involved in the control of spine size (Schratt et al. 2006) .
We recently demonstrated that a class of small RNAs could participate with chromatin-remodeling factors to regulate adult NSCs from the rodent hippocampus. In this study, a small noncoding RNA matching the binding sequence of NRSF, mentioned above, called NRSE small modulatory RNA (or just smRNA), could effectively trigger neurogenesis ). This smRNA appeared to mediate its function in an entirely novel way, unlike siRNAs or miRNAs: It interacted with the NRSF protein and induced neuron-specific gene expression. Clearly, this is just the beginning as we will see many more studies regarding brainenriched small RNAs both in normal physiology and in disease.
CONCLUSIONS
The genome is no longer considered a static and privileged storage depot of genetic information; rather, it is now recognized to be a highly dynamic entity that undergoes profound structural and functional changes in response to extrinsic signals. Epigenetic and transcriptional regulation of the neuronal genome during adult neurogenesis has emerged as one of the best and most useful paradigms to study the role of chromatin modification in cell-fate specification. After cell-fate decisions are triggered, the next step is to determine how master regulators of the neuronal genome interact with their cognate binding partners at sequence-specific binding sites in a context-dependent manner to regulate downstream events controlling neuronal differentiation, maturation, and synaptic plasticity in an ever-changing environment. The fact that many epigenetic processes in the cell can act in a reversible and gene-specific manner allows the precise control of gene expression that is critical for brain development and function. Moreover, epigenetic processes in developing and mature neuronal cells appear to be targeted by a number of pathophysiological stimuli, including seizure activity and drugs such as cocaine. Although these studies are good starting points for studying epigenetic and transcriptional regulation of neuronal target genes, much work is still needed to fully understand the role of master regulators of the neuronal genome such as NRSF. Indeed, small chemical compounds and/or ribonucleic acids would provide excellent tools to begin gaining insight into these regulatory mechanisms and could be the starting points for novel neurological drugs.
